Benefit of Complete Revascularization in Patients With Multivessel Coronary Disease in the Drug-Eluting Stent Era

DOI Web Site PubMed 被引用文献3件 参考文献22件
  • Chung Jin-Wook
    Cardiovascular Center, Seoul National University Hospital Cardiovascular Center, Soonchunhyang University Hospital Cardiovascular Center, Seoul National University Hospital Cardiovascular Center, Soonchunhyang University Hospital
  • Park Keun-Ho
    Cardiovascular Center, Chonnam National University Hospital Cardiovascular Center, Chonnam National University Hospital
  • Lee Min-Ho
    Cardiovascular Center, Seoul National University Hospital Cardiovascular Center, Seoul National University Hospital
  • Park Kyung-Woo
    Cardiovascular Center, Seoul National University Hospital Cardiovascular Center, Seoul National University Hospital
  • Park Jin-Shik
    Cardiovascular Center, Sejong Hospital Cardiovascular Center, Sejong Hospital
  • Kang Hyun-Jae
    Cardiovascular Center, Seoul National University Hospital Cardiovascular Center, Seoul National University Hospital
  • Koo Bon-Kwon
    Cardiovascular Center, Seoul National University Hospital Cardiovascular Center, Seoul National University Hospital
  • Kwon Yoo-Wook
    Innovative Research Institute for Cardiovascular Stem Cells, Seoul National University Hospital Innovative Research Institute for Cardiovascular Stem Cells, Seoul National University Hospital
  • Kim Hyo-Soo
    Cardiovascular Center, Seoul National University Hospital Innovative Research Institute for Cardiovascular Stem Cells, Seoul National University Hospital Molecular Medicine & Biopharmaceuticals Sciences, Seoul National University Cardiovascular Center, Seoul National University Hospital Innovative Research Institute for Cardiovascular Stem Cells, Seoul National University Hospital Molecular Medicine & Biopharmaceuticals Sciences, Seoul National University

この論文をさがす

抄録

Background: The benefit of complete (CR) vs. incomplete revascularization (IR) with drug-eluting stent (DES), unlike with bypass grafting, is not well established in patients with multivessel coronary artery disease (MVD). Methods and Results: Consecutive patients from a single center DES registry who were newly diagnosed as having MVD and who underwent successful percutaneous coronary intervention between March 2003 and December 2009 were traced for the occurrence of death, myocardial infarction (MI), and repeat revascularization. Among 845 patients (337 with CR and 508 with IR), propensity score-matched 275 pairs were followed for a median of 3.9 years. The adjusted hazard ratio (HR) of CR [95% confidence interval] was 0.66 [0.34-1.28] for death; 0.51 [0.28-0.95] for death and MI; 0.84 [0.60-1.19] for death, MI, and repeat revascularization. The observed benefit of CR was also cardiac-specific. The adjusted HR of CR for cardiac death and MI was 0.39 [0.16-0.96]. In 3 subgroups of patients with diabetes (n=191), ejection fraction <55% (n=153) and estimated glomerular filtration rate (eGFR) <60ml/min (n=170), the benefit of CR was pronounced with the adjusted HR for cardiac death and MI of 0.27 [0.08-0.93], 0.18 [0.05-0.68] and 0.27 [0.07-0.99], respectively. Conclusions: In MVD patients treated with DES, CR was associated with the long-term benefit in reducing any or cardiac death and MI. The main beneficiaries of CR were those with diabetes, low ejection fraction and low eGFR.  (Circ J 2012; 76: 1624–1630)<br>

収録刊行物

  • Circulation Journal

    Circulation Journal 76 (7), 1624-1630, 2012

    一般社団法人 日本循環器学会

被引用文献 (3)*注記

もっと見る

参考文献 (22)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ